Heat shock protein-based vaccines and immunotherapies
US7309491B2 · kind B2 · utility
5Cited by
17References
47Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 8, 2004 |
| Grant date | Dec 18, 2007 |
| Priority date | — |
| Expiry date | Apr 8, 2024 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Hybrid antigens comprising at least one antigenic domain, at least one heat shock protein binding domain, and at least one improved peptide linker there between are described which are useful for the induction of an immune response to the antigenic domain when administered alone or in a complex with at least one heat shock protein. The hybrid antigens and complexes can be used to treat infectious diseases and cancers that express an antigen of the antigenic domain.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.